Partnering for better outcomes in treatment-resistant depression.
We partner with healthcare providers across every discipline, from psychiatrists, psychologists, and therapists to primary care physicians and nurse practitioners, to deliver evidence-based TMS care with measurable results. Your patient stays at the center of care, and you stay informed every step of the way.
How would you like to work with us?
Request a referral
Submit a referral and our team will contact your patient to schedule a consultation.
Best when you’d like us to follow up directly with the patient.
ContinuePartner with us
Build an ongoing collaborative relationship. We screen patients for TMS eligibility on your behalf, offer priority scheduling for your referrals, track outcomes with validated measures, and bring advanced treatment options to patients who haven’t responded to standard care.
Best for practices that want a trusted TMS partner for their patients.
ContinueWhy providers partner with NeuroSync
FDA-cleared technology
Ampa One is FDA-cleared for MDD in adults with inadequate response to prior antidepressant medication in the current episode.
Advanced treatment options
Camera-guided Ampa One TMS and an accelerated One-Day Program offer an alternative to weeks of daily visits, with transparent informed consent about its off-label status.
Screening handled for you
Send us patients you think may benefit. Our team handles eligibility screening, safety review, and scheduling, so nothing extra lands on your desk.
Priority access
Your referrals receive priority scheduling and fast callbacks, typically within 1–2 business days.
Measurable, shared results
We track progress with validated measures such as the PHQ-9 and GAD-7. With patient consent, we share outcome updates and return patients to your ongoing care.
Education for your team
Lunch-and-learns and clinical briefings on TMS, patient selection, and the latest research.
Clinical overview
Who may be a candidate
- Patients aged 15 and older with major depressive disorder*
- Unsatisfactory improvement from prior antidepressant medication in the current episode
- Patients who could not tolerate antidepressant side effects (clinical review)
- Patients seeking a non-invasive alternative or add-on to medication
- Patients for whom weeks of daily visits are a barrier (One-Day Program)
Contraindications & cautions
- Non-removable conductive metal in or near the head
- Cochlear implants, DBS, VNS, or other implanted stimulators
- Seizure history, significant head injury, or other neurological conditions (clinical review)
- Acute suicide risk requiring a higher level of care (crisis stabilization first)
- Bipolar disorder, psychosis, active substance use, or pregnancy (clinical review)
Final eligibility is determined by our licensed clinicians after a full evaluation.
*Ampa One is FDA-cleared for major depressive disorder in adults who have not achieved satisfactory improvement from prior antidepressant medication in the current episode. Treatment of patients aged 15–17 is off-label, requires parent or guardian consent, and is approved case by case by our medical director. The One-Day Program is an accelerated schedule that is not itself FDA-cleared and may include prescription medications used off-label.
Let’s start the conversation
Fill out the form and we’ll reach out within 1–2 business days. Prefer to talk now? Call (302) 494-4666.
(302) 494-4666Thank you! We’ll be in touch soon.
A member of our team will reach out within 1–2 business days. We look forward to working together.